Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
30
Recruiting, industry sponsors, Pain and anesthesia, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed965
30 trials
Showing 1 to 25, recently updated first.
- Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral RadiculopathyPivotal-lookingRecruiting
Vertanical GmbHIndustry
NCT06956014 · 810 participants (planned) · Start Sep 22, 2026 · Primary completion Sep 2028
Drug: VER-01 · For: Lumbosacral Radiculopathy
Sites: Mobile, Alabama; Tempe, Arizona; Long Beach, California · 43 sites in all
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)Pivotal-lookingRecruiting
Ambros Therapeutics, Inc.Industry
NCT07210515 · 270 participants (planned) · Start Apr 14, 2026 · Primary completion Dec 2027
Drug: Neridronate; Placebo · For: Complex Regional Pain Syndrome Type I
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 36 sites in all
- Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric PopulationPivotal-lookingRecruiting
SalvatIndustry
NCT05724446 · 60 participants (planned) · Start Jan 4, 2023 · Primary completion Nov 18, 2032
Drug: Clobetasol Propionate; Prednisolone acetate ophthalmic suspension, 1% · For: Cataracts Infantile
Sites: Barcelona, Spain
- The Efficacy and Safety of DLBS1442 in Patients With Primary DysmenorrheaPivotal-lookingRecruiting
Dexa Medica GroupIndustry
NCT07937462 · 210 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 2026
Drug: DLBS1442; Placebo · For: Primary Dysmenorrhea
Sites: Jakarta, Indonesia
- Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue ContusionsPivotal-lookingRecruiting
Aponia Laboratories, Inc.Industry
NCT07930559 · 240 participants (planned) · Start Oct 8, 2026 · Primary completion Jun 2027
Drug: S-Ibuprofen Gel 5%; Vehicle Topical Gel · For: Acute Pain Due to Trauma
Sites: Bend, Oregon; Bonn, Germany; Gilching, Germany · 6 sites in all
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07919678 · 656 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 22, 2028
Drug: Berobenatide · For: Obesity; Overweight; Osteoarthritis of the Knee
Sites: Tempe, Arizona; Escondido, California; Rancho Cucamonga, California · 40 sites in all
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07915609 · 756 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 21, 2028
Drug: Berobenatide; Placebo · For: Obesity; Overweight and/or Obesity; Knee Osteoarthritis and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; Miami, Florida · 4 sites in all
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07353931 · 900 participants (planned) · Start Feb 9, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Osteoarthritis; Overweight or Obesity
Sites: Mobile, Alabama; Mesa, Arizona; Phoenix, Arizona · 147 sites in all
- A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.Pivotal-lookingRecruiting
OncoZenge ABIndustry
NCT07672236 · 150 participants (planned) · Start Jul 7, 2026 · Primary completion Dec 23, 2026
Drug: BupiZenge 25 mg; Lidocaine viscous 2% · For: Head & Neck Cancer; Oral Mucositis
Sites: Copenhagen, Denmark; Herlev, Denmark; Næstved, Denmark · 11 sites in all
- An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical OriginPivotal-lookingRecruiting
Adneuris Therapeutics, Inc.Industry
NCT07845071 · 160 participants (planned) · Start Sep 22, 2026 · Primary completion Jan 2027
Drug: Cebranopadol 400 ug · For: Pain
Sites: Phoenix, Arizona; Riverside, California; Longmont, Colorado · 15 sites in all
- Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1Pivotal-lookingRecruiting
Ambros Therapeutics, Inc.Industry
NCT07857733 · 135 participants (planned) · Start Oct 13, 2026 · Primary completion Dec 31, 2028
Drug: Neridronate · For: Complex Regional Pain Syndrome Type I
Sites: Phoenix, Arizona
- Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal SolutionPivotal-lookingRecruiting
LXO IrelandIndustry
NCT04792034 · 40 participants (planned) · Start Dec 6, 2025 · Primary completion Dec 2027
Drug: Cocaine Hydrochloride Nasal Solution; Cocaine Hydrochloride Nasal Solution · For: ENT Disorder; Nasal Procedures; Nasal Anesthesia and 1 more
Sites: Columbia, South Carolina; Lugoff, South Carolina; Newberry, South Carolina · 6 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc DiseasePivotal-lookingRecruiting
DiscGenics, Inc.Industry
NCT07254806 · 162 participants (planned) · Start Dec 23, 2025 · Primary completion Nov 24, 2027
Drug: IDCT (rebonuputemcel) · For: Degenerative Disc Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 31 sites in all
- YJ001 Spray for Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
NCT07859111 · 400 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 30, 2028
Drug: YJ001 spray simulant; YJ001 spray and 2 more · For: Diabetic Peripheral Neuropathic Pain (DPNP)
Sites: Beijing, China
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in AdultsPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07746726 · 320 participants (planned) · Start Sep 2, 2026 · Primary completion Dec 31, 2026
Drug: HRS-9190; Rocuronium · For: Neuromuscular Blockade
Sites: Changsha, China; Wenzhou, China
- A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute PainPivotal-lookingRecruiting
AFT Pharmaceuticals, Ltd.Industry
NCT07225634 · 60 participants (planned) · Start Sep 14, 2026 · Primary completion Mar 2027
Drug: Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion) · For: Acute Pain
Sites: Budapest, Hungary; Győr, Hungary; Pécs, Hungary · 4 sites in all
- AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07509307 · 400 participants (planned) · Start Apr 20, 2026 · Primary completion Aug 14, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity; Overweight; Osteoarthritis, Knee
Sites: Escondido, California; Lancaster, California; Palm Springs, California · 81 sites in all
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07231419 · 734 participants (planned) · Start Nov 21, 2025 · Primary completion Apr 6, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Glendale, Arizona · 75 sites in all
- Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic NeuralgiaPivotal-lookingRecruiting
Brainfarma Industria Química e Farmacêutica S/AIndustry
NCT07712913 · 348 participants (planned) · Start Jun 18, 2026 · Primary completion Jun 1, 2027
Drug: Experimental: Pregabalin XR; Comparator: Dorene Tabs and 2 more · For: Diabetic Neuropathy; Neuropathic Pain; Neuralgia, Postherpetic
Sites: Salvador, Brazil; Belo Horizonte, Brazil; Vespasiano, Brazil · 15 sites in all
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07709598 · 330 participants (planned) · Start May 11, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Chengdu, China
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07699601 · 330 participants (planned) · Start May 9, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Changsha, China
- A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07481630 · 400 participants (planned) · Start Apr 13, 2026 · Primary completion Aug 14, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111 ) · For: Obesity; Knee Osteoarthritis (OA)
Sites: Phoenix, Arizona; Walnut Creek, California; Hamden, Connecticut · 82 sites in all
- Study of Dapansutrile Tablets in Subjects With an Acute Gout FlarePivotal-lookingRecruiting
Olatec Therapeutics, Inc.Industry
NCT05658575 · 300 participants (planned) · Start Jan 6, 2023 · Primary completion Dec 31, 2026
Drug: Dapansutrile · For: Acute Gout Flare; Gout Attack; Gout Flare and 4 more
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.